Filing Flows › Axsome Therapeutics (AXSM) › Q2 2026 › vs Q2 2025
Axsome Therapeutics (AXSM) Q2 2026 vs Q2 2025 (year over year)
Axsome Therapeutics's revenue rose $68.3M (+46%) from $150M in Q2 2025 to $218M in Q2 2026. The biggest changes: Product +$67.4M (+45%); Royalty and Milestone Revenue +$937K (+87%).
Axsome Therapeutics, Q2 2026: revenue $218M (+46% year over year), operating margin -22.7%, net loss $51.3M, operating cash flow −$33.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $216M | $149M | $67.4M | +45% |
| Royalty and Milestone Revenue | $2.0M | $1.1M | $937K | +87% |
| Revenue | $218M | $150M | $68.3M | +46% |
| Net loss | $51.3M | $48.0M | $3.3M | +7% |
| Costs & expenses | $270M | $199M | $70.7M | +36% |
| Operating costs | $268M | $187M | $81.3M | +44% |
| Interest & other, net | $1.5M | $12.2M | −$10.7M | -87% |
| Income tax | $128K | −$960K | $1.1M | — |
| Operating cash sources | $61.8M | $58.7M | $3.1M | +5% |
| Depreciation & amortization | $1.7M | $1.7M | $23K | +1% |
| Share-based compensation | $27.1M | $24.6M | $2.5M | +10% |
| Cash used in operations | $33.0M | $32.4M | $529K | +2% |
| Net loss absorbed | $51.3M | $48.0M | $3.3M | +7% |
| Working capital & other | $10.5M | $10.8M | −$252K | -2% |
Questions
How much did Axsome Therapeutics's revenue grow year over year in Q2 2026?
Axsome Therapeutics's revenue rose $68.3M (+46%) from $150M in Q2 2025 to $218M in Q2 2026.
What drove Axsome Therapeutics's revenue change in Q2 2026?
Product +$67.4M (+45%); Royalty and Milestone Revenue +$937K (+87%).